It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And the company did it with a big assist from some major league partners in the biopharma industry. Report
Download this whitepaper to learn how risks to safety, quality and productivity can be managed through asset control strategies that also minimize production downtime and improve operational stability. Download now.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!